Efficacy and safety of SilverNovaTM skin cream as adjuvant to oral and topical antifungals in treatment of fungal skin infections

Simple item page
dc.contributor.authorTalathi, A.en_US
dc.contributor.authorJadhav, A.en_US
dc.contributor.authorPurohit, S.en_US
dc.contributor.authorMehta, A.en_US
dc.date.accessioned2024-09-24T09:18:20Z
dc.date.available2024-09-24T09:18:20Z
dc.date.issued2023-09
dc.description.abstractBackground: To evaluate the efficacy and safety of SilverNovaTM skin cream, composed of SilverSolĀ® (a patented colloidal nano silver technology from American Biotech Labs, USA) with other skin rejuvenators (coconut oil, vitamin E, and hyaluronic acid), as an adjuvant to topical and oral antifungals in the treatment of fungal skin infections like tinea and intertrigo. Methods: This prospective clinical study enrolled 80 patients with tinea corporis, tinea cruris, tinea manus, tinea pedis infections, and intertrigo. The patients were randomized to receive either SilverNovaTM skin cream and clotrimazole cream (n=40) or clotrimazole cream (n=40) alone applied topically as an adjuvant to oral antifungal therapy for 14 days. The primary endpoints were the reduction of clinical signs and symptoms of the infection at the end of the treatment and the proportion of patients with therapeutic cures. Results: SilverNovaTM skin cream exhibited better efficacy and safety than clotrimazole cream, though without reaching clinical significance at the end of the treatment. On the 14th day, there was an improvement in clinical signs and symptoms of fissuring/cracking, erythema, maceration, scaling, pruritus, and burning/stinging from baseline in patients with tinea infections, and intertrigo in both the treatment groups. A higher proportion of patients reported therapeutic cures at the end of the treatment, numerically better with SilverNovaTM skin cream group. No drug-related adverse events occurred. Conclusions: SilverNovaTM skin cream is effective and well tolerated as an adjuvant to topical and oral antifungals for the treatment of fungal skin infections like tinea and intertrigo.en_US
dc.identifier.affiliationsSkin Space Clinic, Mumbai, Maharashtra, Indiaen_US
dc.identifier.affiliationsJyoti Multispecialty Clinic, Pune, Maharashtra, Indiaen_US
dc.identifier.affiliationsMavenā€™s Hospital, Ajmer, Rajasthan, Indiaen_US
dc.identifier.affiliationsViridis BioPharma Pvt. Ltd. Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationTalathi A., Jadhav A., Purohit S., Mehta A.. Efficacy and safety of SilverNovaTM skin cream as adjuvant to oral and topical antifungals in treatment of fungal skin infections. International Journal of Research in Medical Sciences. 2023 Sept; 11(9): 3376-3386en_US
dc.identifier.issn2320-6071
dc.identifier.issn2320-6012
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/233555
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber9en_US
dc.relation.volume11en_US
dc.source.urihttps://doi.org/10.18203/2320-6012.ijrms20232796en_US
dc.subjectAgNPsen_US
dc.subjectSilverSolĀ® technologyen_US
dc.subjectDermatophyteen_US
dc.subjectIntertrigoen_US
dc.subjectSeborrheic dermatitisen_US
dc.subjectSilver nanoparticlesen_US
dc.subjectTinea infectionsen_US
dc.titleEfficacy and safety of SilverNovaTM skin cream as adjuvant to oral and topical antifungals in treatment of fungal skin infectionsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijrms2023v11n9p3376.pdf
Size:
436.06 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Research in Medical Sciences